8-Kfiled March 26, 2024, 7:59 PM ETticker BTCYCIK 0001630113
other materialconfidence highsentiment neutralmateriality 0.65
Biotricity raises $1M in private placement of Series B Preferred Stock, with option for additional $1M
BIOTRICITY INC.
Gross proceeds of $1M from sale of 110 Series B Convertible Preferred shares at $9,090.91 each.
Company has 30-day option to require second closing for additional $1M (110 more shares).
Series B Preferred Stock: 8% cumulative dividend (15% upon triggering event), initial conversion price $3.50, alternate conversion at 80% of lowest VWAP.
Registration rights agreement requires filing registration statement within 45 days; failure triggers issuance of 100,000 common shares.
Voting agreement with certain stockholders to support Nasdaq-required stockholder approval for conversion shares issuances.
Extracted from this filing and checked against the source text.
Material AgreementsSEC 8-K Item 1.01/1.02confidence 0.95
BIOTRICITY INC. entered into Purchase Agreement with an institutional investor (effective 2024-03-25).
Action
entry
Agreement
equity purchase
Counterparty
an institutional investor
Effective
2024-03-25
Exact text from the filing
On March 25, 2024, Biotricity Inc. (the “Company”) entered into a security purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the issuance and sale, in a private placement offering (the “Private Placement”), of 110 shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value (the “Series B Preferred Stock”), at a purchase price of $9,090.91 per share of Series B Convertible Preferred Stock, for gross proceeds of $1,000,000.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.